|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Charles M. Baum||Pres, CEO & Director||1,01M||N/D||1958|
|Dr. James G. Christensen||Chief Scientific Officer & Exec. VP||655k||N/D||1968|
|Mr. Daniel R. Faga||Exec. VP, COO & Principal Financial Officer||N/D||N/D||1980|
|Ms. Vickie S. Reed||Sr. VP of Technical Operation & Chief Accounting Officer||N/D||N/D||1962|
|Temre Johnson||Director of Investor Relations & Corp. Communications||N/D||N/D||N/D|
|Ms. Reena R. Desai||VP, Gen. Counsel & Corp. Sec.||N/D||N/D||N/D|
|Mr. Matthew Marx||VP & Head of Drug Discovery||N/D||N/D||N/D|
|Mr. Philip Roberts||Sr. VP of Technical Operations||N/D||N/D||N/D|
|Mr. Benjamin J. Hickey||Exec. VP & Chief Commercial Officer||N/D||N/D||1975|
|Dr. Kelly Covello Ph.D.||VP & Head of Medical Affairs||N/D||N/D||N/D|
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. It is developing MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
L'ISS Governance QualityScore di Mirati Therapeutics, Inc. al 6 ottobre 2020 è 5. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 5; diritti degli azionisti: 4; retribuzione: 8.